Treatment of amyloidogenic diseases
US8613920B2 · kind B2 · utility
40Cited by
188References
36Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 27, 2007 |
| Grant date | Dec 24, 2013 |
| Priority date | — |
| Expiry date | Apr 28, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/56
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides preferred dosage ranges, maximum concentrations, average concentrations and monitoring regimes for use in treatment of Alzheimer's disease using antibodies to Aβ. The invention also provides monitoring regimes that can assess changes in symptoms or signs of the patient following treatment.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.